Kromann Reumert assists in completing a private placement in Zealand Pharma

On 4 October 2022, Zealand Pharma A/S ("Zealand") announced the launch of a private placement of approximately 4.5 million new shares at a price to be determined through an accelerated book-building process. The private placement, which was completed on the same date, was priced at DKK 158 per share and was up-sized to 4,975,000 new shares due to strong demand.

Zealand intends to use the net proceeds from the placement to support the Phase 3 EASE clinical program for glepaglutide and potential regulatory submission for Short Bowel Syndrome, and pursue a strong strategic partner for future commercialization, advance the clinical-stage candidates, including its obesity/metabolic disease portfolio, progress additional peptide candidates into early clinical development and strengthen the company’s capital base and cash preparedness (general corporate purposes).

Kromann Reumert has assisted Danske Bank A/S, Goldman Sachs International and Nordea Danmark, Filial af Nordea Bank Abp, Finland, which acted as Joint Global Coordinators and Joint Bookrunners, and Kempen & Co, which acted as Co-Manager, in connection with the private placement.

Kromann Reumert's core team included Christina Bruun Geertsen and Rune Morthorst.

About Zealand

Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on the discovery, development, and commercialization of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development.

The company has development partnerships with a number of blue-chip pharma companies as well as commercial partnerships for its marketed products.

Founded in 1998, Zealand is headquartered in Copenhagen, Denmark, and has a team in the U.S.